Clinical practice of renal cell carcinoma treatment with nivolumab

被引：0
|
作者：
Potocki, Pawel M. [1 ]
Wysocki, Piotr J. [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Dept Oncol, Krakow, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 05期
关键词：
kidney cancer; renal cell carcinoma; nivolumab; anti-PD-1; immunotherapy; checkpoint inhibitor; RANDOMIZED PHASE-3; CHECKMATE; 025; CANCER; EVEROLIMUS; IMMUNITY; SUNITINIB; BLOCKADE; EFFICACY; THERAPY; SAFETY;
D O I：
10.5603/OCP.2019.0002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nivolumab alike other immune checkpoint inhibitors has been intensively developed during the last decade. Kidney cancer is among the neoplasm in treatment of which we have accumulated the most experience regarding nivolumab. As improves our understanding of the mechanisms underlying specific cellular immune response, thus improves our understanding of the place the nivolumab holds among other therapeutic options. Recent years brought development of innovative immunotherapy combinations as a method for improving immunotherapy efficacy. This review aims at providing practicing oncologists with key aspects of renal cell carcinoma treatment with nivolumab.
引用
收藏
页码：237 / 245
页数：9
相关论文
共 50 条
  • [1] Nivolumab in renal cell carcinoma: latest evidence and clinical potential
    Mazza, Camille
    Escudier, Bernard
    Albiges, Laurence
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (03) : 171 - 181
  • [2] Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
    Joseph, Richard W.
    Chatta, Gurkamal
    Vaishampayan, Ulka
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (04) : 142 - 148
  • [3] Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
    Venur, Vyshak Alva
    Joshi, Monika
    Nepple, Kenneth G.
    Zakharia, Yousef
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1175 - 1182
  • [4] Nivolumab in the treatment of advanced renal cell carcinoma
    Arasaratnam, Malmaruha
    Gurney, Howard
    FUTURE ONCOLOGY, 2018, 14 (17) : 1679 - 1689
  • [5] Nivolumab in the treatment of advanced renal cell carcinoma
    Tomczak, Piotr
    Synowiec, Zuzanna
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (02): : 124 - 126
  • [6] Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma
    Farolfi, Alberto
    Schepisi, Giuseppe
    Conteduca, Vincenza
    Burgio, Salvatore Luca
    Lolli, Cristian
    De Giorgi, Ugo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1089 - 1096
  • [7] Nivolumab in renal cell carcinoma
    Ortega, Rosa M. Michel
    Drabkin, Harry A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (07) : 1049 - 1060
  • [8] The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma
    Ornstein, Moshe C.
    Rini, Brian I.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (06) : 577 - 584
  • [9] Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
    Gao, Xin
    McDermott, David F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (09) : 947 - 957
  • [10] Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma
    Ren, Zongtao
    Niu, Yunfeng
    Fan, Bo
    Wei, Shufei
    Ma, Yongliang
    Zhang, Xiaoyu
    Guo, Xiaoqiang
    Zhang, Aili
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (01) : 584 - 589
12345